IL10 and non-small cell lung carcinoma: To achieve this, we extended our validation of the initial panel of plasma cytokine biomarkers (IL-8, IL-10, and MCP-1) to include additional plasma samples from AA patients diagnosed with stage I NSCLC (Supplementary Table S1).